(Q40359740)

19 September 2017

1 reference

title

Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance (English)

1 reference

19 September 2017

1 reference

3

Joseph L Kuti

1 reference

19 September 2017

4

David P Nicolau

1 reference

19 September 2017

C Andrew DeRyke

1

1 reference

19 September 2017

Su Young Lee

series ordinal

2

1 reference

19 September 2017

publication date

1 January 2006

1 reference

19 September 2017

1 reference

19 September 2017

volume

66

1 reference

19 September 2017

issue

1

1 reference

19 September 2017

page(s)

1-14

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200666010-00001

19 September 2017

exact match

0 references

cites work

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200666010-00001

Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200666010-00001

In vitro synergy and selection of resistance by fluoroquinolones plus amikacin or beta-lactams against extended-spectrum beta-lactamase-producing Escherichia coli

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200666010-00001

Once versus thrice daily gentamicin in patients with serious infections

21 January 2018

1 reference

12 December 2020

Questioning the paradigm: monotherapy vs combination antimicrobial therapy for treatment of Pseudomonas aeruginosa.

1 reference

12 December 2020

Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms

1 reference

12 December 2020

Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring

1 reference

12 December 2020

Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa

1 reference

12 December 2020

Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents

1 reference

12 December 2020

Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model

1 reference

12 December 2020

Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy

1 reference

12 December 2020

Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).

1 reference

12 December 2020

Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia

1 reference

12 December 2020

Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model

1 reference

12 December 2020

Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.

1 reference

12 December 2020

Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy

1 reference

12 December 2020

Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa

1 reference

12 December 2020

A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients

1 reference

12 December 2020

Role for Dual Individualization with Cefmenoxime

1 reference

12 December 2020

Prevention of resistance: a goal for dose selection for antimicrobial agents

1 reference

12 December 2020

Pharmacodynamics of cefepime in patients with Gram-negative infections

1 reference

12 December 2020

National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002.

1 reference

12 December 2020

Pseudomonas bacteremia. Retrospective analysis of 410 episodes

1 reference

12 December 2020

Continuous infusion versus intermittent administration of meropenem in critically ill patients

1 reference

12 December 2020

Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae

1 reference

12 December 2020

Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy

1 reference

12 December 2020

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003.

1 reference

12 December 2020

The pharmacodynamics of beta-lactams

1 reference

12 December 2020

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

1 reference

12 December 2020

Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia

1 reference

12 December 2020

Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia

1 reference

12 December 2020

Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates

1 reference

12 December 2020

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

12 December 2020

Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital

1 reference

12 December 2020

Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae.

1 reference

12 December 2020

Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

1 reference

12 December 2020

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis

1 reference

12 December 2020

Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections

1 reference

12 December 2020

Antimicrobial resistance among gram-negative organisms in the intensive care unit

1 reference

12 December 2020

Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients

1 reference

12 December 2020

Comparison of beta-lactams in counter-selecting resistance of Pseudomonas aeruginosa

1 reference

12 December 2020

The mutant selection window and antimicrobial resistance

1 reference

12 December 2020

Survival strategies of infectious biofilms

1 reference

12 December 2020

Selection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and in three animal models

1 reference

12 December 2020

Once-daily gentamicin versus once-daily netilmicin in patients with serious infections--a randomized clinical trial.

1 reference

12 December 2020

Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates

1 reference

12 December 2020

The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration

1 reference

12 December 2020

Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials

1 reference

12 December 2020

Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002).

1 reference

12 December 2020

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

1 reference

12 December 2020

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

1 reference

12 December 2020

Stretching the mutant prevention concentration (MPC) beyond its limits

1 reference

12 December 2020

Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria

1 reference

12 December 2020

Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy

1 reference

12 December 2020

Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa

1 reference

12 December 2020

Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic model

1 reference

12 December 2020

Molecular epidemiology of selected multidrug-resistant bacteria: a global report from the SENTRY Antimicrobial Surveillance Program

1 reference

12 December 2020

Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong

1 reference

12 December 2020

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

1 reference

12 December 2020

Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia

1 reference

12 December 2020

Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.

1 reference

12 December 2020

Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides

1 reference

12 December 2020

10.2165/00003495-200666010-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

19 September 2017

1008794866

0 references

1 reference